Translational Oncology · 2018 · 31 citations · 13 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyOncogenesAntiviral TherapyHepatocellular CarcinomaHepatocellular Carcinoma PharmacotherapyLiver CancerViral HepatitisViral Hepatitis TreatmentErk SignalingExtracellular Signal-regulated Kinase PathwayMek InhibitionMitogen-activated Protein Kinase CascadesMitogen-activated Protein Kinase PathwaysProtein Kinase InhibitorsRaf-mek-erk SignalingSorafenib Therapy
Hepatitis B virus (HBV) targets the liver and is a major driver for liver cancer. Clinical data suggest that HBV infection is associated with reduced response to treatment with the multi-kinase inhibitor sorafenib, the first available molecularly targeted anti-hepatocellular carcinoma (HCC) drug. Given that Raf is one of the major targets of sorafenib, we investigated the activation state of the Raf-Mek-Erk pathway in the presence of HBV and in response to sorafenib. Here we show that hepatoma cells with replicating HBV are less susceptible to sorafenib inhibitory effect as compared to cells in which HBV expression is suppressed. However, although HBV replication is associated with increased level of pErk, its blockade only modestly augments sorafenib effect. In contrast, the phosphorylated form of the pro-oncogenic Mitogen-Activated Protein Kinase 14 (pMAPK14), a protein kinase that was recently linked to sorafenib resistance, is induced in sorafenib-treated hepatoma cells in association with HBV X protein expression. Knocking down pMAPK14 results in augmentation of the therapeutic efficacy of sorafenib and largely alleviates resistance to sorafenib in the presence of HBV. Thus, this study suggests that HBV promotes HCC resistance to sorafenib. Combining pMAPK14 inhibitors with sorafenib may be beneficial in patients with HBV-associated HCC.
13
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro et al. · New England Journal of Medicine · 2008 · 13K citations · Full text
Medicine, Oncology, Pharmacology +12
Management of Hepatocellular Carcinoma: An Update Δσ
Jordi Bruix, Morris Sherman · Hepatology · 2011 · 8.1K citations · Full text
Sorafenib in Advanced Hepatocellular Carcinoma
재연 정 · 2008 · 5.6K citations
Medicine, Oncology, Pharmacology +12